Shopping Cart 0
Cart Subtotal
USD 0

Isofol Medical AB (ISOFOL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company that develops folate-based therapies for the treatment of cancer patients. The company offers clinical lead candidate Modufolin, a novel folate-based therapy, which is developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It offers active pharmaceutical ingredient (API) of arfolitixorin, which is the key active metabolite of all clinically used folate-based drugs including leucovorin and levoleucovorin. Isofol offers HDMTX rescue therapy with arfolitixorin, which is a common therapeutic regimen in the treatment of osteosarcoma. The company also offers research and development services. Isofol is headquartered in Gothenburg, Sweden.

Isofol Medical AB (ISOFOL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Isofol Medical AB, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Isofol Medical Raises USD1.2 Million in Venture Financing 11

Licensing Agreements 12

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12

Equity Offering 13

Isofol Medical Raises USD48.6 Million in IPO 13

Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14

Isofol Medical AB-Key Competitors 15

Isofol Medical AB-Key Employees 16

Isofol Medical AB-Locations And Subsidiaries 17

Head Office 17

Recent Developments 18

Financial Announcements 18

Nov 20, 2017: Isofol Medical: Interim Report January-September 2017 18

Aug 21, 2017: Isofol Medical: Interim Report 2017 (January 2017-June 2017) 20

Mar 20, 2017: Isofol's Year-End Report January-December 2016 22

Corporate Communications 24

Sep 11, 2018: New Chairman and extended board at Isofol Medical 24

Product News 25

11/27/2017: Isofol announces that an abstract regarding Modufolins efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018 25

10/03/2017: Isofol appoints Gustaf Albert as Chief Financial Officer 26

09/11/2017: Isofol announces that Modufolin as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities 27

08/24/2017: From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin in patients with metastatic colorectal cancer 28

08/18/2017: Isofols appoints Sven Erickson as Chief Commercial Officer 29

08/16/2017: Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin 30

07/03/2017: New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study 31

06/21/2017: Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin is evaluated in colorectal cancer 32

05/22/2017: Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting 33

05/03/2017: Isofol Accepted for Presentation of Abstract at the 2017 ASCO Annual Meeting 34

04/11/2017: Isofol has successfully completed the ISO-MTX-003 study in which Modufolin is evaluated as rescue therapy 35

02/08/2018: Isofol reports successful outcome from the scientific advice with the EMA 36

01/18/2018: Positive treatment results with Modufolin (arfolitixorin) will be published at a cancer congress in the US 37

01/11/2018: Isofol Announces Positive Efficacy Data For Modufolin (Arfolitixorin) In Patients Treated For Metastatic Colorectal Cancer 38

Product Approvals 39

Sep 04, 2017: Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin for treatment of metastatic colorectal cancer 39

Clinical Trials 40

Feb 19, 2018: Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin 40

Jan 17, 2018: Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin agreed 41

Jul 24, 2017: Isofol Announces that an Abstract about Modufolin in Osteosarcoma Treatment will be Presented at ESMO 2017 42

Jul 05, 2017: Isofol Has Enrolled And Dosed Its First Group Of Patients In The Ind-study Iso-ff-001 43

Jan 24, 2017: FDA Clears Isofol'S IND Application To Start Clinical Program Within Colorectal Cancer With Modufolin 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Isofol Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Isofol Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Isofol Medical Raises USD1.2 Million in Venture Financing 11

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12

Isofol Medical Raises USD48.6 Million in IPO 13

Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14

Isofol Medical AB, Key Competitors 15

Isofol Medical AB, Key Employees 16

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Isofol Medical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company that develops folate-based therapies for the treatment of cancer patients. The company offers clinical lead candidate Modufolin, a novel folate-based therapy, which is developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It offers active pharmaceutical ingredient (API) of arfolitixorin, which is the key active metabolite of all clinically used folate-based drugs including leucovorin and levoleucovorin. Isofol offers HDMTX rescue therapy with arfolitixorin, which is a common therapeutic regimen in the treatment of osteosarcoma. The company also offers research and development services. Isofol is headquartered in Gothenburg, Sweden.

Isofol Medical AB (ISOFOL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Isofol Medical AB, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Isofol Medical Raises USD1.2 Million in Venture Financing 11

Licensing Agreements 12

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12

Equity Offering 13

Isofol Medical Raises USD48.6 Million in IPO 13

Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14

Isofol Medical AB-Key Competitors 15

Isofol Medical AB-Key Employees 16

Isofol Medical AB-Locations And Subsidiaries 17

Head Office 17

Recent Developments 18

Financial Announcements 18

Nov 20, 2017: Isofol Medical: Interim Report January-September 2017 18

Aug 21, 2017: Isofol Medical: Interim Report 2017 (January 2017-June 2017) 20

Mar 20, 2017: Isofol's Year-End Report January-December 2016 22

Corporate Communications 24

Sep 11, 2018: New Chairman and extended board at Isofol Medical 24

Product News 25

11/27/2017: Isofol announces that an abstract regarding Modufolins efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018 25

10/03/2017: Isofol appoints Gustaf Albert as Chief Financial Officer 26

09/11/2017: Isofol announces that Modufolin as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities 27

08/24/2017: From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin in patients with metastatic colorectal cancer 28

08/18/2017: Isofols appoints Sven Erickson as Chief Commercial Officer 29

08/16/2017: Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin 30

07/03/2017: New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study 31

06/21/2017: Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin is evaluated in colorectal cancer 32

05/22/2017: Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting 33

05/03/2017: Isofol Accepted for Presentation of Abstract at the 2017 ASCO Annual Meeting 34

04/11/2017: Isofol has successfully completed the ISO-MTX-003 study in which Modufolin is evaluated as rescue therapy 35

02/08/2018: Isofol reports successful outcome from the scientific advice with the EMA 36

01/18/2018: Positive treatment results with Modufolin (arfolitixorin) will be published at a cancer congress in the US 37

01/11/2018: Isofol Announces Positive Efficacy Data For Modufolin (Arfolitixorin) In Patients Treated For Metastatic Colorectal Cancer 38

Product Approvals 39

Sep 04, 2017: Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin for treatment of metastatic colorectal cancer 39

Clinical Trials 40

Feb 19, 2018: Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin 40

Jan 17, 2018: Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin agreed 41

Jul 24, 2017: Isofol Announces that an Abstract about Modufolin in Osteosarcoma Treatment will be Presented at ESMO 2017 42

Jul 05, 2017: Isofol Has Enrolled And Dosed Its First Group Of Patients In The Ind-study Iso-ff-001 43

Jan 24, 2017: FDA Clears Isofol'S IND Application To Start Clinical Program Within Colorectal Cancer With Modufolin 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Isofol Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Isofol Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9

Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Isofol Medical Raises USD1.2 Million in Venture Financing 11

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12

Isofol Medical Raises USD48.6 Million in IPO 13

Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14

Isofol Medical AB, Key Competitors 15

Isofol Medical AB, Key Employees 16

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Isofol Medical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.